Compare IIIN & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IIIN | DBVT |
|---|---|---|
| Founded | 1953 | 2002 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.9M | 508.8M |
| IPO Year | N/A | N/A |
| Metric | IIIN | DBVT |
|---|---|---|
| Price | $33.13 | $19.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.04 |
| AVG Volume (30 Days) | 114.8K | ★ 439.7K |
| Earning Date | 01-15-2026 | 10-28-2025 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | ★ 112.14 | N/A |
| EPS | ★ 2.10 | N/A |
| Revenue | ★ $647,706,000.00 | $5,502,000.00 |
| Revenue This Year | $14.97 | $1,768.71 |
| Revenue Next Year | $7.00 | $1,028.88 |
| P/E Ratio | $15.82 | ★ N/A |
| Revenue Growth | ★ 22.39 | N/A |
| 52 Week Low | $22.49 | $2.74 |
| 52 Week High | $41.64 | $21.50 |
| Indicator | IIIN | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 63.13 | 72.42 |
| Support Level | $31.34 | $12.75 |
| Resistance Level | $32.24 | $21.50 |
| Average True Range (ATR) | 0.69 | 1.13 |
| MACD | 0.39 | 0.72 |
| Stochastic Oscillator | 92.04 | 70.34 |
Insteel Industries Inc produces and sells prestressed concrete strand (PC strand) and welded wire reinforcement (WWR). PC strand, a high-strength seven-wire cable, is used to strengthen precast concrete in structures like bridges, parking decks, and buildings, enabling longer spans and slimmer designs. WWR includes engineered structural mesh for primary reinforcement, concrete pipe reinforcement for drainage and sewage systems, and standard WWR for crack control in residential and light commercial construction. The company serves markets in the United States and internationally, with the majority of revenue generated in the United States.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.